Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Other Non-Current Assets: 2018-2025

Historic Other Non-Current Assets for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to $13.7 million.

  • Bicycle Therapeutics' Other Non-Current Assets rose 37.95% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.7 million, marking a year-over-year increase of 37.95%. This contributed to the annual value of $11.1 million for FY2024, which is 91.19% up from last year.
  • As of Q3 2025, Bicycle Therapeutics' Other Non-Current Assets stood at $13.7 million, which was down 0.70% from $13.8 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Other Non-Current Assets registered a high of $13.8 million during Q2 2025, and its lowest value of $2.2 million during Q1 2021.
  • Its 3-year average for Other Non-Current Assets is $9.8 million, with a median of $10.6 million in 2023.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first soared by 151.69% in 2023, then tumbled by 45.83% in 2024.
  • Over the past 5 years, Bicycle Therapeutics' Other Non-Current Assets (Quarterly) stood at $3.4 million in 2021, then skyrocketed by 145.30% to $8.5 million in 2022, then crashed by 31.52% to $5.8 million in 2023, then surged by 91.19% to $11.1 million in 2024, then spiked by 37.95% to $13.7 million in 2025.
  • Its Other Non-Current Assets stands at $13.7 million for Q3 2025, versus $13.8 million for Q2 2025 and $12.4 million for Q1 2025.